Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
1.725
-0.095 (-5.22%)
Mar 31, 2025, 1:13 PM EDT - Market open
Nuvation Bio Revenue
In the year 2024, Nuvation Bio had annual revenue of $7.87M. Nuvation Bio had revenue of $5.71M in the quarter ending December 31, 2024.
Revenue (ttm)
$7.87M
Revenue Growth
n/a
P/S Ratio
62.13
Revenue / Employee
$35,786
Employees
220
Market Cap
584.22M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NUVB News
- 5 days ago - Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 - Business Wire
- 6 days ago - Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 - Business Wire
- 24 days ago - Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners - Business Wire
- 5 weeks ago - Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 5 weeks ago - Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PRNewsWire
- 6 weeks ago - Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst - Seeking Alpha
- 2 months ago - Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire